RxDoctor Payments Data

Adam Taintor, MD

Dermatology · Ogden, UTNPI 1851563779

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.6% of the total across 237 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $957, 3.0 times the $318 reported in 2019.

$3,933in general payments, 2019–2025

Across 237 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$915
  • AbbVie$698
  • Johnson & Johnson$397
  • Sanofi$243
  • Pfizer$224
  • Galderma Laboratories, L.p.$220
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$3,76096%
  • Education$1724%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,933 in reported general payments places this provider in the 70th percentile of 163 dermatology providers in Utah.

See all dermatology providers in Utah

Medicare billing

Part B allowed, 2024
$256,770
Medicare patients
750
Services billed
5,328

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa24$548,077
Dupixent SyringeDupilumab19$85,212
Clindamycin Phosphate108$5,206
Clobetasol Propionate68$5,138
Fluocinonide132$5,103
Ketoconazole245$3,748
Fluconazole55$3,043
Doxycycline Monohydrate86$2,901
Metronidazole64$2,726
Triamcinolone Acetonide231$2,683
Econazole Nitrate59$2,670
Fluorouracil23$2,243
Betamethasone Valerate11$1,597
Calcipotriene13$1,487
Doxycycline Hyclate33$1,304

Paid to pharmacies, not to this prescriber.

Other dermatology in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →